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Epidemiology of Radiation-Induced Cancer
by Edward P. Radford*
The epidemiology ofradiation-induced cancer is important for theoretical and practi-
cal insights thatthese studies give to human cancer in general and because we have more
evidence from radiation-exposed populations than for any other environmental carcino-
gen. On theoretical and experimental grounds, the linear no-threshold dose-response
relationship is a reasonable basis for extrapolating effects to low doses. Leukemia is
frequently the earliest observed radiogenic cancer but is now considered to be of minor
importance, because the radiation effect dies out after 25 or 30 years, whereas solid
tumors induced by radiation develop later and the increased cancer risk evidently
persists for the remaining lifetime. Current estimates of the risk of particular cancers
from radiation exposure cannot be fully evaluated until the population under study have
been followed at least 40 or 50 years after exposure. Recent evidence indicates that for
lung cancer induction, combination ofcigarette smoking and radiation exposure leads to
risks that are not multiplicative but rather nearly additive.
I believe an important reason that radiation-
induced cancer is especially pertinent to the dis-
cussion today is because it is frequently related to
a definition ofthe acceptability ofrisk (1). Radia-
tion provides a useful model ofways ofevaluating
risks from all environmental agents, because we
have more information about health effects of
radiation in human populations than we have for
any other environmental agent of which I am
aware (2). Thus it is critical that we look at the
evidence relating radiation to cancer and discuss
some of the problems that exist in interpreting
the epidemiologic data.
I would like to begin by presenting some theo-
retical concepts which follow a point made by
Upton (2). With respect to cellular effects ofradia-
tion on DNA, and we believe radiation carcino-
genesis is at least associated with phenomena
having to do with cellular DNA, ifE represents
an incremental effect ofradiation, say, on cancer
incidence, then we can express E as a function of
dose D in an equation ofthe form,
E = (aD = bD2) exp { - aD - 13D2} (1)
where a, b, a and are empirical constants. The
first two terms are of a linear and quadratic form
and relate mutagenic or carcinogenic probability
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to radiation dose. Then there is an exponential
term related to cell survival probability; for can-
cer to occur, the cell or cells transformed have to
survive to lead to descendants which eventually
form a cancer. The negative exponent means that
as dose increases, survival decreases.
This mathematical formulation fits closely the
experimental data presented by Upton (2). The
ratio ofthe constant b to constant a, which I take
to be about 0.01 when the dose D is in rads, is
close to the value given by Upton for this ratio of
the quadratic and linear component. For the ex-
ponential term also the ratio 13/a is also about
0.01 for acute cell killing, again in agreement
with Upton. With the assumption ofthese values,
Eq. (1) takes the form
E = aD(1 + 0.01D) exp - {aD (1 + 0.O1D)} (2)
whenD is in rads.
If you plot this curve, with an assumption of
0.001 for a based on cell survival studies, you find
that it is close to a straight line up to a dose of
about 250 rads. It is actually slightly sigmoid
because of the dose squared (bD2) term, but the
effect ofthe exponential term almost cancels out
the effect of the quadratic term and the result
comes out close to a straight-line relationship. If
we apply classical radiobiological principles to
dose-response curves, which Upton has so ele-
gantly presented, Eqs. (1) and (2) are consistent
with a large literature oftheoretical and experi-E. P. RADFORD
mental data. They also support the linear no-
threshold approximation for definition of the
dose-response relationship, such as for cancer in-
duction.
In practice, some of the factors we have to
consider in evaluating epidemiologic evidence of
cancer risk from radiation exposure include: ex-
posure conditions, special risks by age, applica-
tion of the absolute risk versus the relative risk
models, the latent period from exposure to onset
of cancer, and finally the duration ofthe carcino-
genic effects. These last two points are important
because there has been, I think, a lot ofconfusion
inthe minds ofmany people about the duration of
the effect, even by some who are quite knowledge-
able about this subject. For example, from early
studies that were carried out, especially on the
Japanese A-bomb survivors, it was found that
leukemia was the cancer that appeared first in
excess. Subsequently, it became apparent that
this effect ofradiation, given in this case virtually
instantaneously, was dying out, inthat the excess
leukemia was disappearing in the population. As
of1974, 30 years after the bombing, it had almost
completely disappeared (3). In other words, the
increased risk of leukemia rose approximately 2
years after the bomb, went through a maximum
at about 8 to 10 years, and then has declined back
again to the expected rate after 25 to 30 years.
Because leukemia showed the first significant
increase in cancer risk in this population, it has
received special attention for this reason. Other
populations that have been studied, such as the
British spondylitics mentioned by Dr. Upton, also
showed very much the same kind of time course
for leukemia (4). It turns out, however, that this
time course for excess cancer is the exception, not
the rule, and almost all other solid cancers being
found in irradiated populations, including the
Japanese A-bomb survivors, have much longer
latent periods to onset, and have not shown a
decline with time, at least up to the present. The
indications are now that excess risk ofnearly all
other cancers will probablypersist for the lifetime
ofthe population exposed. One ofthe most impor-
tant conclusions that can be derived from this
statement is the fact that when we add up all of
the cancers that may be produced by radiation,
those which come on much later and have a
longer latent period to onset, such as cancers of
the female breast, thyroid, lung, or intestinal
tract, become much more important than leuke-
mia. In fact, it is fair to say now that leukemia is
a minor cancer produced by radiation. The princi-
pal reason for this is because ofthe difference in
the duration of the effect. Individuals irradiated
at, say, age 20 or 30, have a long life-span in
which they subsequently can develop cancer, and
the fact that excess risk of cancers other than
leukemia presumably will not die out over time
makes these cancers much more important in
terms of a lifetime cancer risk. In view of these
considerations, the degree ofemphasis some peo-
ple place on radiogenic leukemia is unwarranted.
Tb illustrate the long duration of cancer effects,
Table 1 shows some recent data derived from a
group of 1400 Swedish iron miners. Here ob-
served and expected lung cancer deaths are given
as a function oftime after starting mining. These
miners were exposed to quite low concentrations
of radon daughters, the concentrations in these
mines being very close to the standard currently
in operation for U.S. miners. So these data give a
preview of what we can anticipate from under-
ground miners in the U.S. today if they are ex-
posed at or near the current exposure limit.
As a function of years since they began under-
ground mining, the observed versus the expected
cases oflung cancer did not rise until 20 or more
years after they began mining. At 50+ years
there is still an excess, and furthermore, from 20
years to more than 50 years, the relative risk
stays essentially constant. That is, the ratio of
observed to expected cases shows no statistically
significant difference over time. There is a 3.4-
fold excess risk of lung cancer for the whole
group, taken from 10 years after the beginning of
mining. In other words, our current standard
Table 1. Lung cancer deaths by years since began underground; period ofobservation 1951-76.
Years since began underground
Lung cancer deaths 0-9 10-19 20-29 30-39 40-49 50 + Total
Observed 1 1 7 14 23 5 51
Expected, based on Swedish national rates 0.27 0.99 2.28 4.54 5.19 1.61 14.87
Observed/expected 3.71 1.01 3.08** 3.08** 4.44** 3.11* 3.43**
Lower confidence limit (a = 0.025) 0.09 0.03 1.24 1.68 2.81 1.01 2.55
Upper confidence limit (a = 0.025) 20.63 5.60 6.34 5.17 6.66 7.27 4.51
*Significant at 5%* level.
**Significant at 1% level.
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gives rise to approximately 3.4-fold risk of lung
cancer compared to an unexposed population. The
point I am making here is that the effect persists
after long periods of time. The mean duration of
work underground was about 20 years for these
miners, so most ofthe group had stopped mining
by 30 years after beginning, and therefore little
or no further exposure took place after that time.
Yet the risk is persisting out to 50 or more years.
Let us now consider some ofthe classic epidemi-
ologic data on radiation-induced cancer in human
populations. Figure 1 shows data on mortality
from all cancers except leukemia plotted against
radiation dose for the Japanese A-bomb survi-
vors. These data were as of follow-up to 1974.
Results for the two cities, Hiroshima and Naga-
saki, are presented independently. A very long
acrimonious tale hangs upon this particular
graph, I can assure you. If a dose-response curve
is fitted over all ofthe data points for Nagasaki,
the slope is very different than that for Hiro-
shima, and this lower slope was considered to be
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very important, even though it depended largely
on the difference in the two cities at one single
data point. If you fit only the lowest dose points
which are somewhat stronger epidemiologically,
there is little difference between the two cities.
The difference was thought to be in the neutron
component ofthe two bombs. The Nagasaki pluto-
nium bomb was considered to have few neutrons,
while the Hiroshima U-235 bomb was thought to
have a significant neutron component. More re-
cent evidence,just developed within the last year,
indicates that infactthe 1965 dosimetry inJapan
was wrong, and there was no significant amount
ofneutrons in Hiroshima after all, and therefore,
that argument cannot be used to explain this
difference.
Another important point to note is that this
graph deals with cancer mortality. There has
been some discussion at this symposium of the
inaccuracy ofmortality statistics. The major can-
cers that arise from radiation, such as breast,
thyroid, and even lung cancer, are not well repre-
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FIGURE 1. Mortality from all cancers except leukemia, Japanese A-bomb survivors,
1955-1974, both sexes combined: (left) Hiroshima; (right) Nagasaki. Ordinate:
deaths per thousand per year age-adjusted to total population. Abscissa: mean
tissue dose in rem derived from coefficients ofKerr, and on assumption that the
neutron component inboth cities had a constant RBE of5. Vertical bars represent
80% confidence limits for individual points. Dashed lines show weighted linear
regression applied to data below 100 rem. Reprinted by permission from Radford
(5).
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sented in these mortality data. For example, the
reason that lung cancer mortality is uncertain is
that in Japan the diagnosis of lung cancer on
death certificates is really quite inaccurate, un-
like in the United States. Autopsy comparisons
among the A-bomb survivors have shown that
almost one-halfofthe cases identified at autopsy
are not correctly assigned to lung cancer on death
certificates.
Fortunately, we have other data. Figure 2 is
cancerincidence data from the tumor registries in
the two cities for the period 1959-1970. In this
case we findthere is very little difference between
the two cities. There is a slightly greater slope in
Hiroshima compared to Nagasaki, but unlike the
mortality results, the incidence data are reasona-
bly consistent with the linear no-threshold dose-
response curve in both cities. Granted, there are
large error limits for the data points and from
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these results one cannot distinguish a straight
line from a slightly curved dose-response.
The results shown in these graphs are now
made obsolete by the new dose estimates for the
A-bomb survivors. Only recently I received from
Dr. Loewe at the Livermore Laboratory a more
detailed basis on which I could calculate how the
old dose data would change with the new evi-
dence. The principal effect is that the slope ofthe
line in both cities will be higher, especially in
Nagasaki, and nearly all the dose is now from -y-
radiation in Hiroshima as well as in Nagasaki.
Therefore, the cancer incidence results are
strongly supportive ofa similar dose-response for
the two cities. Thus, the radiation-induced cancer
effect is the same in the two cities, and we can
now combine the data and improve the epidemio-
logic reliability ofestimates ofeffect at low doses.
Ipredict thatby the final follow-up ofthis popula-
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FIGURE 2. Cancer incidence for all cancers except leukemia, Japanese A-bomb
survivors, 1959-1970, both sexes combined: (left) Hiroshima; (right) Nagasaki.
Ordinate: incidence, cases per thousand peryear age-adjusted to total population.
Abscissa: mean tissue dose in rem as in Figure 1. Vertical bars represent 80%
confidence intervals for individual points. The line drawn is the weighted linear
regression, whichfits all datapoints well, withoutthe marked irregularity ofhigh
dose points seen in Figure 1. The population bases for the incidence and mortality
studies are the same; the difference is dependent on mode of ascertainment of
cases. Reprinted by permission from Radford (5).
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tion, it will be possible to show a significant
excess of cancer at about 10 rads y-dose or per-
haps less, because ofthe size ofthe study popula-
tion andthefactwe cannow combine results from
the two cities.
The leukemia data, again with the old 1965
dosimetry, show a slight upward curvilinearity in
both cities, but because of the dose uncertainty
the dose-response for leukemia will also have to
be separately reevaluated. Nevertheless, the leu-
kemia results were a main basis for the decision
to use the linear-quadratic equation in the BEIR
III report (5).
This evidence from theJapanese A-bomb survi-
vors is important because of the fact that they
have a range of doses and they also were a sub-
stantial sized population-about 48,000 actually
exposed to more than minimal doses. Other data
are available for comparison. Figure 3 shows the
incidence ofbreast cancer in relation to radiation
dose in four groups ofwomen (6). For the A-bomb
survivors, in the upper left-hand graph, a rather
irregular dose response is found, but significant
effects at relatively low doses are present. Note
that both cities are combined in this study be-
cause no difference was found even with the pre-
vious dose estimates. On the upper right-hand
graph were women irradiated during collapse
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therapy for tuberculosis who received a breast
dose as a result of multiple chest fluoroscopies.
Exposure for these women was to repeated small
doses: the average dose to breast tissue was esti-
mated at 1.5 rads per fluoroscopy, and on average
each woman had about 100 exposures. On the
lower left are shown results for a group ofwomen
in New York who were given X-ray therapy for
post-partum mastitis. In this case from one to
four doses to the breast tissue was given. Finally
the lower right graph is from a group of Nova
Scotia women also given fluroscopies for collapse
therapy. In this case there is no estimate ofdose,
and the abscissa is presented simply as number of
fluoroscopies.
The significant point from these studies illus-
trates another important factor in the use of
epidemiology in the definition ofrisk, and there-
fore, as a basis for standard-setting, namely, rep-
lication of results. The risk coefficients derived
from the three studies in which there are quanti-
tative dose data are remarkably similar. Because
these three studies, with y- or X-ray exposures for
very different reasons, and with different ethnic
backgrounds and usual breast cancer rates, give
closely similar radiation risk coefficients, consid-
erable strength is added to the data for each.
Another important question is the strength of
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FIGURE 3. Incidence of breast cancer in
permission from Boice et al. (6).
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data at low doses. For example, Modan's study of
thyroid cancer in 10,000 Israeli children given X-
ray treatments for ringworm of the scalp found
evidence of thyroid cancer excess at less than 9
rads total dose to the thyroid (7). In the Swedish
iron miners discussed above we have found dou-
bling of observed over expected cases at cumula-
tive dose of 27 working level months, a unit of
cumulative dose ofa-radiation from radon daugh-
ters, only about five times background for people
exposed to indoor radon daughters at home. As
some of you know, the question of radon daugh-
ters in houses is now becoming a major public
health concern. We can, in other words, use epide-
miologic methods to try to define the dose-re-
sponse curve by working with groups exposed to
radiation doses as low as we can conceivably
demonstrate a significant effect. The effects inves-
tigated should involve the cancer types most sen-
sitive to radiation.
Upton (2) emphasized that for y rays and X-
rays, spreading the dose out over time would
perhaps be expected to reduce the effect. In the
case of exposures to alpha radiation, spreading
out the dose over time appears to increase the
effect. Therefore the rate at which radiation expo-
sure occurs is a variable modifying the carcino-
genic potential.
Another point has to do with the question of
synergism between two environmental agents. In
the case of lung cancer, the cigarette smoking
experience becomes important. One ofthe signifi-
cant things we have been able to do in our study
of Swedish iron miners has been to evaluate
smoking independently. We have been able to
calculate smoking-specific expected rates in this
population. The risk per unit dose per million
person years at risk is not greatly different for
smokers and nonsmokers in this case. That is
contrary to what people have generally been say-
ing about radiation-induced lung cancer. It was
said that the effect ofsmoking was multiplicative
with the radiation exposure. My belief is the
reasonwhy we have found no multiplicative effect
phenomenon is because we have much longer
follow-ups than for most other mining popula-
tions exposed to radon daughters. Thus I believe
thatprevious statements about the multiplicative
effects ofsmoking may be epidemiologic artifacts
ofa short follow-up time. Ifthe onset ofradiation-
induced cancer in nonsmokers is delayed, then
the risk could be strongly dependent on how long
the people are studied.
Thus, effects ofincomplete follow-up are a gen-
eral problem in interpreting any epidemiologic
study. For a disease like cancer, with a long time
from initiation to expression, a final resolution of
many issues relating exposure to cancer risk may
require study of the population for nearly their
lifetime. For example, the A-bomb survivors are
far from having completed their lifetimes. Some
ofthe current data indicate that if an individual
were irradiated at age 20 he might have a lower
risk than someone radiated at age 60. But if the
projections found thus far apply, because the 20-
year old has a longer life-span available, the
actual lifetime risk is greater for the younger
individual than it is for the older individual.
We are now in a position to predict, using life
table techniques, how much lifetime risk of can-
cer will occur under various radiation exposure
regimens. This permits the regulatory process to
proceed with the best science we have today.
There remain a number ofassumptions that have
to be made, but as follow-up studies extend in
time, we should have good evidence on which to
resolve the remaining questions. I believe that
within ten years our assessment of radiation-
induced cancer should be quite precise.
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